Medtronic Diabetes:
People using the Guardian’ Connect system will also have exclusive access to the groundbreaking Sugar.IQ’ smart diabetes assistant, empowering them to further address the daily challenges of diabetes. With the Guardian’ Connect system, the Sugar.IQ’ assistant can turn difficult-to-determine patterns into personalized insights that help people with diabetes keep glucose levels in their target range. The company has been the leader in insulin pumps dating back decades and was the first to launch a combo device with a continuous glucose monitor (CGM).
“Diabetes Freedom is not just about managing numbers, it’s about reclaiming the joy in life. It’s about the sweet victory of a balanced meal, the triumph of an active day, and the peace that comes from knowing you’re in control Click here to read more...”
Initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% increase in Time in Range (TIR) and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. This improvement was even greater overnight with a TIR increase of 30.2%. At the close of the 6-month study period, all participants on MDI + isCGM crossed over to the MiniMed 780G system. At one year, these significant improvements were reproduced in this cross-over group and sustained in those that started on AHCL therapy at the start of the trial. The Guardian’ Connect continuous glucose monitoring (CGM) system allows you to see glucose levels, trends and alerts on your mobile device.
Medtronic especially doesn’t have the most successful track record in this area. Remember the BD FlowSmart technology that was launched as the Medtronic Pro set? That didn’t last long, as reports of kinked cannulas led to the initial product being pulled from the market by Medtronic.
“Embrace Diabetes Freedom as a journey of empowerment. It’s the courage to make healthy choices, the strength to maintain discipline, and the wisdom to seek help when needed. It’s about living life on your terms, not dictated by a condition Click here to read more...”
The MiniMed’ 630G system has an intuitive design and several convenient features that can help your patients succeed with their diabetes management. Ironically, many in the #WeAreNotWaiting DIY (do-it-yourself) diabetes innovation community are still using these older insulin pump models, as they remain quite reliable and ‘ cover your ears, FDA and diabetes educators leery of off-label product use ‘ are able to be hacked. We finally saw the end of an era as to Medtronic’s original insulin pump models that looked like colorful pagers in 2018. Those are still widely used but are now officially discontinued and no longer available to buy.
With type 2 diabetes, the pancreas can still make some insulin, but either it doesn’t make enough, or the body’s cells don’t respond to it as effectively as they used to. When the cells don’t respond as effectively, this is called ‘insulin resistance.’ This means glucose is not getting into the cells where it’s needed to function properly. Type 2 diabetes is often referred to as ‘adult onset’ or ‘insulin non-dependent’ click here for info diabetes. With type 2 diabetes, the pancreas can still make insulin, but either it doesn’t make enough, or the body’s cells don’t respond to it as effectively as they used to. ‘ At the time of manufacture and when the reservoir and tubing are properlyinserted, your pump is waterproof. It is protected against the effects of beingunderwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours.
“Diabetes Freedom is the dawn after the darkest night. It’s the resilience to face challenges, the determination to make lifestyle changes, and the patience to see the results. It’s about transforming adversity into an opportunity for a healthier life Click here to read more...”
Alert settings that meet your needsBe notified 10 to 60 minutes before your glucose is out of range. Helping you take action before your glucose is out of rangeThe Guardian Connect system is the only CGM that offers alerts up to 60 minutes in advance of a high or low. Predictive alerts can help you take action sooner, giving you more time to prevent your levels from going out of range. Diabetes is a condition in the body where blood sugar levels are higher than normal. This can happen when the body either doesn’t make any insulin (type 1 diabetes), or the insulin that the body makes doesn’t work well (type 2 diabetes). This is why it’s important that people with type 2 diabetes work with their healthcare team to ensure they are effectively managing their diabetes.
The MiniMed’ 508 insulin pump is introduced, offering new features such as remote programming capabilities to administer or suspend insulin delivery, the ability to program multiple patient-specific delivery patterns, a low volume alert, optional vibrate mode, and child-block. The MiniMed 630G insulin pump system delivers insulin and monitors glucose levels, allowing you to deliver your insulin more easily than multiple daily injections. Before now, insulin pumps have been Medtronic’s only delivery method offered to patients; but now by buying its way into the smart insulin pen market, there will be a new option for those who choose injections rather than pump therapy.
“Diabetes Freedom is a testament to human willpower. It’s about the silent battles won with every healthy meal, every step taken, every glucose reading. It’s a celebration of life, a commitment to health, and a pledge for a brighter, healthier future Click here to read more...”
The Guardian’ 4 Sensor is intended for use with the MiniMed’ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The Guardian’ (4) sensor is indicated for up to seven days of continuous use. The Guardian’ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required.
Medtronic has been slow to seek a ‘non-adjunctive’ status for their CGM sensors that would eliminate the requirement for fingerstick confirmations and allow for Medicare coverage. While every other CGM competitor has snagged this FDA designation, Medtronic has dragged its feet on pursuing it. It’s always a question as to when something will even be submitted to FDA, let alone actually approved, but considering the FDA’s breakthrough designation granted for this investigational device in 2019, it may not be too far off. We are committed to providing #ExtraordinaryExperiences for our customers, and are here to assist you with the support you may need every step of the way. When it comes to diabetes technology, we believe it can and should do more for you.
The iPro2′ digital recorder is intended to continuously record interstitial glucose levels in persons with diabetes mellitus. This information is intended to supplement, not replace, blood glucose information obtained using standard home glucose monitoring devices. The information collected by the iPro2′ digital recorder may be uploaded to a computer (with Internet access) and reviewed by healthcare professionals. The information may allow identification of patterns of glucose-level excursions above and below a desired range, facilitating therapy adjustments, which may minimize these excursions.
Medtronic will begin taking pre-orders on May 15, 2023, with first shipments planned for later this summer. Customers on the company’s MiniMed’ 770G system today will be eligible to upgrade their device to the MiniMed 780G through a see no-cost, remote software upgrade. See important safety information page and the appropriate user guides for additional important details. ‘ Assumes four injections per day for 30 days and one infusion set change every three days.
For patients who experience chronic pain due to DPN and have not been satisfied by the levels of relief provided by oral pain medication, injections, or other treatments for pain, SCS can provide a new approach for patients looking for solutions. In-person and online medical education programs and trainings designed to help you better support your patients using read what he said therapies. We are committed to providing you with the level of support to help your patients reach their diabetes goals. We encourage you to place your next order when you open your last box of supplies to ensure your order has enough time to process. For your pump supplies, Medicare requires Medtronic to confirm the number of supplies that you have on hand before we can ship your next supply order.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Quick Release is introduced, providing customers with a new level of freedom and flexibility by allowing them to temporarily detach from the insulin pump at the infusion site without having to insert a new infusion set. FDA approves the first-of-its-kind mySentry Remote Glucose Monitor, which allows a parent or caregiver to monitor a patient’s MiniMed’ Paradigm’ REAL-Time Revel’ system from another room.